Published in AJR Am J Roentgenol on June 01, 2005
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer (Neonab) | NCT01830244
Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol (2008) 2.52
Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology (2009) 2.45
Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer (2006) 1.54
Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy. Philos Trans A Math Phys Eng Sci (2011) 1.38
Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer? Radiology (2011) 1.14
Fluorescence tomography characterization for sub-surface imaging with protoporphyrin IX. Opt Express (2008) 1.11
Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology (2008) 1.10
Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat (2011) 1.10
Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient. Acad Radiol (2010) 1.09
Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol (2010) 1.08
Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol (2006) 1.07
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience. Breast Cancer Res (2013) 1.05
Diffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy. IEEE J Sel Top Quantum Electron (2011) 1.05
Automated chest wall line detection for whole-breast segmentation in sagittal breast MR images. Med Phys (2013) 1.04
Monitoring therapeutic efficacy in breast carcinomas. Eur Radiol (2006) 1.03
Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. Am J Surg (2006) 0.99
Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol (2010) 0.98
Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. J Magn Reson Imaging (2010) 0.96
The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: a preliminary study. Eur Radiol (2009) 0.95
Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results. Magn Reson Imaging (2013) 0.94
Computer-aided evaluation of breast MRI for the residual tumor extent and response monitoring in breast cancer patients receiving neoadjuvant chemotherapy. Korean J Radiol (2011) 0.94
Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol (2013) 0.92
Malignant lesion segmentation in contrast-enhanced breast MR images based on the marker-controlled watershed. Med Phys (2009) 0.90
MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One (2013) 0.90
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology (2015) 0.88
Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy. Breast Cancer (Dove Med Press) (2012) 0.87
Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol (2008) 0.86
Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017. Ann Surg Oncol (2014) 0.86
Combined MR, fluorescence and histology imaging strategy in a human breast tumor xenograft model. NMR Biomed (2012) 0.86
Effect of the enhancement threshold on the computer-aided detection of breast cancer using MRI. Acad Radiol (2009) 0.85
Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators. Eur Radiol (2014) 0.84
High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Acad Radiol (2013) 0.83
Treatment response assessment of breast masses on dynamic contrast-enhanced magnetic resonance scans using fuzzy c-means clustering and level set segmentation. Med Phys (2009) 0.83
Accuracy of MRI volume measurements of breast lesions: comparison between automated, semiautomated and manual assessment. Eur Radiol (2009) 0.82
Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study. BMC Cancer (2011) 0.81
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.81
Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging (2013) 0.81
Spatial registration of temporally separated whole breast 3D ultrasound images. Med Phys (2009) 0.80
Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Medicine (Baltimore) (2016) 0.79
Monitoring of tumor response to Cisplatin using optical spectroscopy. Transl Oncol (2014) 0.79
Preoperative MRI improves prediction of extensive occult axillary lymph node metastases in breast cancer patients with a positive sentinel lymph node biopsy. Acad Radiol (2014) 0.79
Quantification of Ultrasonic Scattering Properties of In Vivo Tumor Cell Death in Mouse Models of Breast Cancer. Transl Oncol (2015) 0.79
Evaluation of an automatic registration-based algorithm for direct measurement of volume change in tumors. Int J Radiat Oncol Biol Phys (2011) 0.78
Computer-aided detection (CAD) system for breast MRI in assessment of local tumor extent, nodal status, and multifocality of invasive breast cancers: preliminary study. Cancer Imaging (2015) 0.78
Are we HER-ting for innovation in neoadjuvant breast cancer trial design? Breast Cancer Res (2009) 0.77
Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One (2016) 0.77
High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies. Br J Cancer (2008) 0.77
Early prediction of response to neoadjuvant chemotherapy for locally advanced breast cancer using MRI. Nagoya J Med Sci (2011) 0.76
Dedicated Breast CT: Feasibility for Monitoring Neoadjuvant Chemotherapy Treatment. J Clin Imaging Sci (2014) 0.76
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography (2016) 0.75
Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment. J Natl Cancer Inst Monogr (2015) 0.75
Voxelwise analysis of simultaneously acquired and spatially correlated (18) F-fluorodeoxyglucose (FDG)-PET and intravoxel incoherent motion metrics in breast cancer. Magn Reson Med (2016) 0.75
Microcirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer. Magn Reson Imaging (2012) 0.75
Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer. Eur Radiol (2016) 0.75
Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer. Breast Cancer Res (2016) 0.75
Image guided near-infrared spectroscopy of breast tissue in vivo using boundary element method. J Biomed Opt (2011) 0.75
Prediction of Mild Cognitive Impairment Conversion Using a Combination of Independent Component Analysis and the Cox Model. Front Hum Neurosci (2017) 0.75
Prediction of pathological complete response of breast cancer patients undergoing neoadjuvant chemotherapy: usefulness of breast MRI computer-aided detection. Br J Radiol (2014) 0.75
Thermal tomography for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer. Oncotarget (2017) 0.75
Automatic segmentation of subcutaneous mouse tumors by multiparametric MR analysis based on endogenous contrast. MAGMA (2014) 0.75
Three-dimensional segmentation of breast masses from digital breast tomosynthesis images. J Med Imaging (Bellingham) (2017) 0.75
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
The yeast cell-cycle network is robustly designed. Proc Natl Acad Sci U S A (2004) 6.76
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2010) 4.62
Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res (2004) 4.48
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
On the use of general control samples for genome-wide association studies: genetic matching highlights causal variants. Am J Hum Genet (2008) 3.95
Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. Ann Intern Med (2014) 3.78
Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J Bone Miner Res (2004) 3.77
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Osteoarthritis: MR imaging findings in different stages of disease and correlation with clinical findings. Radiology (2003) 3.36
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology (2012) 3.36
T2 relaxation time of cartilage at MR imaging: comparison with severity of knee osteoarthritis. Radiology (2004) 3.24
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol (2005) 3.11
The UCSC Cancer Genomics Browser. Nat Methods (2009) 3.08
Management of autoimmune retinopathies with immunosuppression. Arch Ophthalmol (2009) 2.97
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol (2012) 2.75
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2012) 2.62
Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci U S A (2005) 2.59
Diffusion tensor imaging: serial quantitation of white matter tract maturity in premature newborns. Neuroimage (2004) 2.58
Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. Radiology (2007) 2.48
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. Plast Reconstr Surg (2012) 2.37
Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology (2002) 2.26
Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol (2003) 2.16
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol (2012) 2.05
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol (2002) 2.00
Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. Ann Surg Oncol (2002) 1.99
Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2004) 1.98
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev Res (Phila) (2010) 1.91
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med (2012) 1.85
New two-dimensional metal-organic networks constructed from 1,2,4,5-benzenetetracarboxylate and chelate ligands. Inorg Chem (2003) 1.83
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res (2011) 1.78
Distinguishing features of self-limiting adult small-bowel intussusception identified at CT. Radiology (2003) 1.76
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol (2008) 1.74
Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res (2003) 1.71
Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA (2010) 1.71
Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. Arch Surg (2010) 1.70
Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology (2004) 1.69
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
Nociception in persistent pancreatitis in rats: effects of morphine and neuropeptide alterations. Anesthesiology (2003) 1.69
The draft genome of the fast-growing non-timber forest species moso bamboo (Phyllostachys heterocycla). Nat Genet (2013) 1.68
Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology (2002) 1.68
Designing verbal autopsy studies. Popul Health Metr (2010) 1.64
Transit-amplifying cell frequency and cell cycle kinetics are altered in aged epidermis. J Invest Dermatol (2009) 1.57
Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum (2011) 1.55
Adaptation of the proximal femur to skeletal reloading after long-duration spaceflight. J Bone Miner Res (2006) 1.55
Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol (2014) 1.50
Comparing BMD results between two similar DXA systems using the generalized least significant change. J Clin Densitom (2008) 1.48
Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg (2002) 1.47
Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging (2004) 1.47
Comparison of bootstrap approaches for estimation of uncertainties of DTI parameters. Neuroimage (2006) 1.47
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46
Tractography-based quantitation of diffusion tensor imaging parameters in white matter tracts of preterm newborns. J Magn Reson Imaging (2005) 1.46
Sodium channel genes and the evolution of diversity in communication signals of electric fishes: convergent molecular evolution. Proc Natl Acad Sci U S A (2006) 1.45
MRI and CT of insufficiency fractures of the pelvis and the proximal femur. AJR Am J Roentgenol (2008) 1.44
Selective inflammatory pain insensitivity in the African naked mole-rat (Heterocephalus glaber). PLoS Biol (2008) 1.43
Breast cancer risk assessment and prevention: a framework for shared decision-making consultations. Breast J (2006) 1.43
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat (2010) 1.42
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Res Treat (2015) 1.42
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol (2008) 1.42
Old gene duplication facilitates origin and diversification of an innovative communication system--twice. Proc Natl Acad Sci U S A (2010) 1.41
Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer (2004) 1.40
Current Trends in the Management of Ductal Carcinoma In Situ. Oncology (Williston Park) (2016) 1.39
Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients. Ann Surg (2009) 1.39
Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. NMR Biomed (2006) 1.38
Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn (2011) 1.37